Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05635721
Other study ID # P.T.REC/012/004076
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 5, 2022
Est. completion date January 26, 2023

Study information

Verified date January 2023
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

BACKGROUND: The deep peroneal nerve arises as a branch of the common peroneal nerve which courses around the neck of the fibula. The motor component of deep peroneal nerve is responsible for innervating the anterior compartment of the lower leg which includes the tibialis anterior, extensor hallucis longus, extensor digitorum longus, and peroneus tertius muscles. Nerve conduction velocity shortly known as "NCV" tests are used determine the speed of the electrical signals moving along a specific peripheral nerve .This will be helpful in localizing the site of entrapment of peripheral nerves and useful for assessing both recovery and prognosis of any injury to peripheral nervesthere are numerous aspects that could influence nerve conduction study. Although changes in joint position have been reported in several studies to affect nerve conduction velocity of peripheral nerves. the effect of changing ankle joint position on deep peroneal NCV has not been repor Purpose This study will investigate the effect of different ankle positions on: 1. Deep peroneal nerve distal motor latency across ankle joint. 2. Deep peroneal nerve sensory onset latency across ankle joint


Description:

31healthy subjects of both genders with age ranging from 20to 40years old were examined for motor distal latency and sensory onset latency at three different ankle positions :neutral,20degrees dorsiflexion and 40degrees plantar flexion


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date January 26, 2023
Est. primary completion date January 3, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 40 Years
Eligibility Inclusion criteria: - Healthy subjects. - Age ranges from 20 to 40 years because longer latencies and slower nerve conduction velocity are seen significantly with increasing age. - All participants will be selected with body mass index (BMI) between 18.5 and 24.9kg/cm2 . Exclusion criteria: - Elderly subjects. - Pregnant women. - Subjects with history of or risk factors for peripheral nerve lesions. - Obese subjects. - Subjects with any foot deformity. - History of lower limb fractures. - History of surgery to lower limbs - Diabetic patients. - Patients with cardiovascular disorders. - Hypertensive patients. - Women wearing high heeled shoes.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Mahmoud Salah Aga

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Deep peroneal nerve motor distal latency Motor distal latency: It is the time between the distal stimulus and the onset of compound muscle action potential(CMAP)at recording muscles 30 minutes for each participant
Primary Deep peroneal nerve sensory onset latency : It is the time taken from the stimulus artifact to the initial negative deflection of the sensory nerve action potential (SNAP) 30 minutes for each participant
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1